The maximum gene alteration rate of DCLRE1B was recorded for pan-cancer patients with uterine corpus endometrial carcinoma, skin cutaneous melanoma, mesothelioma and pheochromocytoma and paraganglioma with deep deletion (> 3%) as the primary type (Fig. 8B). This evidence concerns the gene DCLRE1B and cutaneous melanoma.